Interchangability -- It's more than just biosimilars

by: |
03/06/2013

In case you think the issue of interchangability is only relevant to the biosimilars debate, have a look at this story from the New York Times.

The tort bar is watching -- and salivating.

And patient care is suffering.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Interchangability -- It's more than just biosimilars

Latest from CMPI

Coronavirus: America’s drug supply needs a refill

Prescription for Failure: The Ills of Socialized Medicine (CPAC 2020)

How to eliminate surprise medical bills

Keep Canadian drugs out of U.S. medicine cabinets

Blog Roll

Categories